PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs NVO |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 0.21 | 12.7 | 61.0% | +138% |
| NVS | Novartis AG | 1.53 | 23.5 | 15.4% | +1639% |
| LLY | Eli Lilly and Company | 1.55 | 42.6 | 27.5% | +1661% |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.85 | 16.3 | 5.7% | +3150% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.48 | 28.4 | 8.2% | +3861% |